2-Deoxy-D-glucose: Redefining Immunometabolic Research and Tumor Microenvironment Modulation

Introduction

The metabolic landscape of cancer and infectious diseases is shaped by the intricate interplay of cellular bioenergetics and immune regulation. 2-Deoxy-D-glucose (2-DG), a glucose analog and potent glycolysis inhibitor, enables researchers to unravel and manipulate these complex pathways with unprecedented precision. While prior reviews have focused on 2-DG’s role as a metabolic pathway research tool and its synergy in translational workflows (see this advanced toolkit perspective), this article uniquely dissects the emerging role of 2-DG in immunometabolic reprogramming—specifically, its impact on tumor-associated macrophages (TAMs) and the tumor microenvironment (TME). We also integrate recent mechanistic breakthroughs, such as lysosomal AMP kinase (AMPK) activation and mTORC1-STAT6 signaling, to provide a comprehensive roadmap for advanced research applications.

Mechanism of Action of 2-Deoxy-D-glucose (2-DG)

Glycolysis Inhibition and ATP Synthesis Disruption

2-Deoxy-D-glucose (2-DG) functions as a competitive glycolytic inhibitor by mimicking glucose and entering cells via glucose transporters. Upon phosphorylation by hexokinase to 2-DG-6-phosphate, it cannot be further metabolized by phosphohexose isomerase. This metabolic dead-end disrupts glycolytic flux, resulting in a profound reduction in ATP synthesis and the induction of metabolic oxidative stress. Such energy depletion triggers metabolic checkpoints that are particularly relevant in rapidly proliferating cells, including cancer cells and virally infected cells.

Metabolic Oxidative Stress Inducer

By impeding the glycolytic pathway, 2-DG acts as a potent metabolic oxidative stress inducer. This metabolic stress modulates cellular responses and can drive apoptosis or sensitize cells to chemotherapeutic agents. In tumor cells, the reliance on aerobic glycolysis (the Warburg effect) makes them particularly susceptible to glycolytic blockade, positioning 2-DG as a central player in glycolysis inhibition in cancer research.

Interference with PI3K/Akt/mTOR Signaling

2-DG’s disruption of ATP production also impinges on the PI3K/Akt/mTOR signaling pathway, a crucial axis for cell growth, survival, and immune modulation. The downstream effects include altered protein synthesis, autophagy induction, and modulation of immune cell phenotypes—factors central to cancer progression and immune escape.

2-DG in the Tumor Microenvironment: Beyond Cancer Cell Targeting

Reprogramming Tumor-Associated Macrophages (TAMs)

Recent evidence, as elucidated in a landmark study by Xiao et al. (Immunity 2024), reveals that metabolic reprogramming within the TME extends far beyond cancer cells. TAMs, key mediators of immunosuppression in 'cold' tumors, accumulate 25-hydroxycholesterol (25HC), activating lysosomal AMPK via the GPR155-mTORC1 complex. This cascade leads to STAT6 phosphorylation, promoting an immunosuppressive macrophage phenotype and ARG1 production. Strikingly, targeting cholesterol-25-hydroxylase (CH25H) in macrophages can switch cold tumors to hot, enhancing antitumor immunity even in the absence of checkpoint blockade.

2-DG, by disrupting glycolysis and depleting ATP, can selectively stress immunosuppressive TAMs, potentially modulating their metabolic programming. The interplay between 2-DG-induced AMPK activation and the mTORC1-STAT6 axis suggests a new paradigm: modulation of macrophage fate via metabolic intervention. This goes beyond previously reviewed roles of 2-DG as a metabolic pathway inhibitor, introducing its capacity to reshape the immune landscape of tumors.

Synergy with Chemotherapy and Tumor Sensitization

In animal models, 2-DG synergizes with chemotherapeutic agents such as Adriamycin and Paclitaxel, dramatically slowing tumor growth in xenografts of human osteosarcoma and non-small cell lung cancer (NSCLC). This effect is mediated not only by direct cytotoxicity but also by disrupting the metabolic crosstalk within the TME—including KIT-positive gastrointestinal stromal tumor treatment and non-small cell lung cancer metabolism.

Comparative Analysis with Alternative Methods

While other glycolytic inhibitors and metabolic pathway research tools exist, 2-DG is distinguished by its dual utility as both a research probe and a therapeutic sensitizer. Previous articles, such as "2-Deoxy-D-glucose: Precision Glycolysis Inhibition in Cancer", have emphasized experimental workflows and troubleshooting. Here, we uniquely focus on the immunometabolic consequences of glycolysis inhibition—specifically, the modulation of macrophage and T cell phenotypes within the tumor microenvironment, which is not extensively discussed in the prior literature.

Additionally, other metabolic modulators (e.g., metformin, dichloroacetate) influence mitochondrial metabolism or oxidative phosphorylation, but lack the glycolytic specificity and translational synergy of 2-DG. Unlike broad-spectrum inhibitors, 2-DG’s mimicry of glucose allows for targeted intervention in both cancer and immune cell metabolism, offering unparalleled versatility for dissecting AMPK/mTORC1/STAT6 signaling dynamics.

Advanced Applications in Cancer Immunometabolism

Modulating the Tumor Microenvironment

The immunosuppressive TME is a major barrier to effective immunotherapy. As demonstrated in the Xiao et al. study, TAMs reprogram their metabolism in response to microenvironmental cues, accumulating 25HC to activate AMPK and drive STAT6-dependent immunosuppression. By interfering with glycolysis and ATP synthesis, 2-DG can potentially tip the metabolic balance, re-educating TAMs and enhancing CD8+ T cell infiltration and activation. This is a distinct perspective from previous articles, such as "2-Deoxy-D-glucose: Precision Glycolysis Inhibition in Cancer", which focus on experimental optimization rather than immunometabolic reprogramming.

KIT-positive Gastrointestinal Stromal Tumor and NSCLC Applications

2-DG exhibits marked cytotoxicity against KIT-positive GIST cell lines (IC₅₀ values: 0.5 μM for GIST882; 2.5 μM for GIST430) and has demonstrated efficacy in combination regimens for NSCLC. Its solubility profile (≥105 mg/mL in water; ≥2.37 mg/mL in ethanol; ≥8.2 mg/mL in DMSO) and recommended working concentrations (5–10 mM for 24 hours) make it highly adaptable for in vitro and in vivo studies targeting glycolysis inhibition in cancer research.

Viral Replication Inhibition and Antiviral Research

Beyond oncology, 2-DG’s ability to impair viral protein translation and replication—such as in porcine epidemic diarrhea virus (PEDV) models—broadens its utility. By targeting the metabolic dependencies of viral replication, 2-DG serves as a valuable viral replication inhibition tool, complementing direct-acting antivirals and opening new avenues for host-directed antiviral strategies.

Integrative Immunometabolic Workflows

Advanced protocols now integrate 2-DG with metabolic flux analysis, single-cell RNA sequencing, and immunophenotyping to dissect the interactions between glycolytic inhibition, AMPK/mTORC1/STAT6 signaling, and immune cell function. This integrated approach, rarely explored in previous content, positions 2-DG at the forefront of next-generation immunometabolic research.

Best Practices and Experimental Considerations

Due to its high water solubility and stability at -20°C (with avoidance of long-term solution storage), 2-DG is ideally suited for diverse experimental setups, from cell culture to animal models. When designing experiments, it is essential to titrate the compound for cell-type specificity and to monitor for off-target effects, especially in immune cell-rich environments. Combining 2-DG with chemotherapeutics or immunomodulators should be guided by precise metabolic and phenotypic readouts to maximize translational relevance.

Conclusion and Future Outlook

2-Deoxy-D-glucose (2-DG) is rapidly evolving from a classical glycolysis inhibitor into a multifaceted tool for immunometabolic reprogramming and tumor microenvironment modulation. By disrupting glycolytic flux and ATP synthesis, 2-DG not only induces metabolic oxidative stress and enhances the efficacy of chemotherapeutics but also holds the potential to re-educate immunosuppressive macrophages and boost T cell antitumor responses. The integration of recent mechanistic insights—such as the AMPK/mTORC1/STAT6 axis described by Xiao et al. (2024)—heralds a new era for metabolic interventions in cancer and virology.

As metabolic pathway research tools continue to advance, 2-Deoxy-D-glucose (2-DG) stands out as a uniquely versatile compound. Its expanding applications in immunometabolism, tumor microenvironment tuning, and viral replication inhibition promise to accelerate the translation of metabolic discoveries into clinical innovations. For further exploration of actionable workflows and advanced troubleshooting in metabolic research, readers may consult this comprehensive resource, which complements our focus here by offering practical laboratory insights.